202 related articles for article (PubMed ID: 19965913)
1. A case of bullous dermatitis induced by erlotinib.
Oteri A; Cattaneo MT; Filipazzi V; Ferrario S; Gambaro A; Isabella L; Tosca N; Clementi E; Radice S; Piazza E
Oncologist; 2009 Dec; 14(12):1201-4. PubMed ID: 19965913
[TBL] [Abstract][Full Text] [Related]
2. Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva).
Lübbe J; Masouyé I; Dietrich PY
Dermatology; 2008; 216(3):247-9. PubMed ID: 18182820
[TBL] [Abstract][Full Text] [Related]
3. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
4. Purpuric drug eruption and alopecia induced by erlotinib.
Nakamura-Wakatsuki T; Yamamoto T
Dermatol Online J; 2012 May; 18(5):16. PubMed ID: 22630586
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Santoro F; Cozzani E; Parodi A
J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
[TBL] [Abstract][Full Text] [Related]
6. Rosaceiform eruption induced by erlotinib.
Patrizi A; Bianchi F; Neri I
Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
[TBL] [Abstract][Full Text] [Related]
7. Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects.
Gerber PA; Enderlein E; Homey B; Muller A; Boelke E; Budach W
J Clin Oncol; 2007 Oct; 25(29):4697-8; author reply 4698-9. PubMed ID: 17925571
[No Abstract] [Full Text] [Related]
8. Erlotinib-induced scalp perifolliculitis.
Rallis E; Petronic-Rosic V; Korfitis C
Skinmed; 2012; 10(2):70-1. PubMed ID: 22545319
[TBL] [Abstract][Full Text] [Related]
9. Acneiform reaction to erlotinib.
Schalock PC; Zug KA
Dermatitis; 2007 Dec; 18(4):230-1. PubMed ID: 18021605
[TBL] [Abstract][Full Text] [Related]
10. Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
Campbell TM; Brown CW
J Drugs Dermatol; 2008 Dec; 7(12):1161-3. PubMed ID: 19137770
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
[TBL] [Abstract][Full Text] [Related]
12. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
Bragg J; Pomeranz MK
Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
[TBL] [Abstract][Full Text] [Related]
13. Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
Benomar S; Boutayeb S; Afifi Y; Hamada S; Bouhllab J; Hassam B; Errihanni H
Dermatol Online J; 2009 Nov; 15(11):2. PubMed ID: 19951638
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
Ong CK; Tan WC; Chan LC; Abdul Razak M
Med J Malaysia; 2012 Apr; 67(2):222-3. PubMed ID: 22822651
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
[TBL] [Abstract][Full Text] [Related]
16. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib induced target-like purpura.
Rungtrakulchai R; Rerknimitr P
Dermatol Online J; 2014 Feb; 20(2):. PubMed ID: 24612572
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib induced skin rash spares skin in previous radiotherapy field.
Mitra SS; Simcock R
J Clin Oncol; 2006 Jun; 24(16):e28-9. PubMed ID: 16735697
[No Abstract] [Full Text] [Related]
19. [Henoch-schönlein purpura induced by erlotinib (Tarceva): a case report].
Yuba T; Nagata K; Shiotsu S; Okano A; Hatsuse M; Murakami S; Morihara K; Shimazaki C
Nihon Kokyuki Gakkai Zasshi; 2010 Jan; 48(1):81-5. PubMed ID: 20163028
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
